ArticleScientific reports2023
Coagulation markers as independent predictors of prostate cancer aggressiveness: a retrospective cohort study.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.Biochemistry and biophysics reports · 2026Article
- Integrated Bulk and Single-Cell Transcriptomics Reveals the C3-C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma.Biomedicines · 2026Article
- Development and Validation of a Novel Indicator for Differential Diagnosis of Clinically Significant Prostate Cancer Based on Comprehensive Hematological Testing.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic Role of Prostate-Specific Antigen (PSA) in male patients hospitalized for COVID-19.Pakistan journal of medical sciences · 2025Article
- Coagulation markers as independent predictors of colorectal cancer aggressiveness.BMC gastroenterology · 2025Article
- D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy.Journal of gastrointestinal oncology · 2025Article
- SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.Cancer medicine · 2025Article
- Radium levels in Brazil nuts: A review of the literature.Nutrition bulletin · 2025Review
- Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights.Frontiers in immunology · 2025Review
- Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis.Journal of Cancer · 2025Article
- Predictive model based on blood cell analysis and coagulation function indicators for neuroblastic tumors staging diagnosis.Frontiers in oncology · 2025Article
- Carbon dots derived fromFrontiers in molecular biosciences · 2025Article
- Prognostic value of fibrinogen change value in adrenocortical carcinoma patients.Discover oncology · 2024Article
- A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using ProteographInternational journal of molecular sciences · 2024Article
- Peripheral Coagulation Parameters and Prostate Cancer Association: A Retrospective Study and Mendelian Randomization.Clinical Medicine Insights. Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coagulation system activation is commonly observed in tumor patients, including prostate cancer (PCa), with coagulation markers proposed as potential prognostic indicators for cancer severity. However, the correlation between these markers and clinicopathological features in PCa remains unclear. Thus, this study investigates the association between comprehensive coagulation markers and clinicopathological characteristics in PCa patients. A retrospective evaluation of 162 PCa patients diagnosed and categorized into low-intermediate-risk or high-risk groups based on clinical and pathological features was conducted. Coagulation markers, including fibrinogen (FIB), D-dimer (DD), activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin activity (PTA), thrombin time (TT), platelet count (PLT), and international normalized ratio (INR), were assessed. Univariate and multivariate logistic regression analyses were performed to determine associations with clinicopathological features. FIB and DD were confirmed as independent factors associated with high-risk PCa. Furthermore, FIB and DD levels showed significant positive correlations with clinical parameters, including PSA levels, ISUP grade, T stage, N stage, and M stage. Our findings suggest that FIB and DD hold promise as independent prognostic biomarkers for risk stratification in PCa. These coagulation markers may aid in assessing PCa severity and guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.